Drugs / HSK41959
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07699757 | Jul 2026 → Apr 2029 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06968572 | Apr 2025 → Mar 2026 overdue | cancer | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK41959 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07699757 ↗ |
| Route | Oral | “Oral administration, QD” NCT06968572 ↗ |